Nephros Inc Stock Price, News & Analysis

Nephros, a company focused on water purification and pathogen detection, announced it will release its third quarter 2020 financial results on November 5, 2020, after market close. The company will also host a conference call at 4:30 PM ET on the same day to discuss financial results and provide a business overview. Nephros targets medical and commercial markets with ultrafilters and pathogen detection systems, crucial for infection control in healthcare settings.

Nephros, Inc. (Nasdaq: NEPH) announced a registered direct offering of 833,333 shares at $6.00 each, estimated to gross $5.0 million. The offering's expected closure is on or around October 20, 2020, subject to customary conditions. Proceeds will be allocated for working capital and general corporate purposes. The shares are offered under an effective shelf registration statement filed with the SEC. B. Riley Securities is the lead financial advisor for this offering.

Nephros, Inc. (Nasdaq: NEPH) has announced the launch of DialyPath, an innovative assay that rapidly estimates endotoxin levels in dialysis water samples within two hours. This on-site testing solution is designed to enhance patient safety by identifying waterborne bacterial contamination, correlating highly with the industry-standard LAL assay. With a lower limit of quantification at 0.001 EU/ml, DialyPath significantly improves testing efficiency compared to traditional methods that take 2-3 days. The product does not rely on endangered horseshoe crab blood cells, making it a more sustainable choice.

Nephros, Inc. (Nasdaq: NEPH), a company specializing in high-performance water purification and pathogen detection systems, will present at the MicroCap Rodeo Best Ideas Bowl from October 13-16, 2020. Scheduled for October 13 at 11:30 AM ET, the presentation will be webcast live for attendees. The conference features 25 select companies, recommended as top ideas by institutional investors, aiming to showcase potential investment opportunities. Nephros is known for its ultrafilters used in various medical and commercial applications, ensuring water safety and quality.

Nephros, Inc. (Nasdaq: NEPH) reported preliminary financial results for Q3 2020, showing net revenues of $2.1 million, a 34% increase from Q2 2020 but a 32% decrease from Q3 2019. The company holds approximately $5.2 million in cash. CEO Andy Astor highlighted the ongoing impact of the COVID-19 pandemic on new customer acquisition and sales in hospitality sectors. However, he noted strong recurring revenue from existing customers and positive progress in product development and market opportunities, including in food and beverage sectors.

Nephros, Inc. (NASDAQ: NEPH) will present at the LD 500 virtual investor conference on September 1, 2020, at 10:20 am ET. CEO Andy Astor will share insights about the company's advanced water purification and pathogen detection systems designed for medical and commercial markets. The LD 500 conference runs from September 1 to 4, 2020, and registration is available online. Nephros aims to continue its commitment to infection control and water safety through its innovative ultrafilters and detection systems.

Nephros (Nasdaq: NEPH) announces a leadership transition, appointing Andy Astor as President and CEO effective August 24, 2020. Daron Evans, the current CEO, will continue as Senior Science Advisor and CEO of Specialty Renal Products. Astor, who joined Nephros in 2017, has played a pivotal role in revenue growth by four-fold and fostering strong investor relations. With over 1,100 active customer sites, the company focuses on water purification and pathogen detection systems, key to infection control in healthcare settings.

Nephros, Inc. (Nasdaq:NEPH) reported a net revenue of $1.6 million for Q2 2020, down 32% from $2.3 million in 2019 due to COVID-19 interruptions. The consolidated net loss increased to $1.7 million from $0.9 million year-over-year, and adjusted EBITDA was ($1.4 million), compared to ($0.5 million) in 2019. Despite these challenges, CEO Daron Evans expressed optimism about future growth, citing early Q3 market signs and new product developments like SequaPath™ and DialyPath™. The company maintains a cash position of $7.0 million.

Nephros, a company specializing in water purification and pathogen detection systems, will release its second quarter 2020 financial results on August 5, 2020. The management will host a conference call at 4:30 PM ET to discuss these results and provide a business overview. Interested parties can join by calling 1-844-808-7106 (domestic) or 1-412-317-5285 (international). A replay will be available until August 12, 2020.

Nephros’s products include ultrafilters for medical facilities and commercial filters aimed at improving water quality.